Figure 5
From: New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53
Effects of SM13 on tumour growth in vivo. (A) To validate in vitro results, we studied the effects of SM13 in vivo in Balb/c nude mice. Tumour growth was measured twice a week by a caliper during all the treatment long (14 days of treatment). Intra-peritoneal treatment (IP: 5 mg Kg–1) or low doses (low: 1 mg Kg–1) of SM13 retard tumour growth compared with controls and are more effective of ISA27 at the same dosages. High doses (high: 3 mg Kg–1) reduce tumour volumes back to the starting size. Results are the mean of measurements from five mice per group (*P<0.05 vs control). Figure also shows a representative image of tumours at the end of the treatment. (B) Tumours size was taken at the end of the treatment and the percent of reduction of tumour growth was calculated in tumours treated with ISA27 and SM13 with respect to controls. SM13 is able to inhibit tumour growth more efficiently than SM13 (*P<0.05 vs ISA27). (C) Tumours were homogenized to confirm by western blot analysis the effect of SM13 on mitochondrial-dependent apoptotic signalling. In treated tumours, SM13 increases protein levels of Bax and citochrome c, and activates both caspase 9 and caspase 3. Images are the mean of five independent experiments.
